GH Research PLC Market Cap ($1.39 Billion)
Market Cap & Net Worth: GH Research PLC (GHRS)
GH Research PLC market cap. GH Research PLC (NASDAQ:GHRS) has a market capitalization of $1.39 Billion ($1.39 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7238 globally and #2243 in its home market, demonstrating a 5.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GH Research PLC's stock price $20.28 by its total outstanding shares 68642287 (68.64 Million). Also see GHRS operating cash flow for how efficiently the company converts equity into cash flow.
GH Research PLC Market Cap History (2021–2026)
GH Research PLC market cap history from 2021 to 2026. Data shows growth from $1.60 Billion to $1.39 Billion (0.98% CAGR). Check GH Research PLC stock price for real-time trading data and today's change.
Index Memberships
GH Research PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.05% | #213 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #819 of 3165 |
Weight: GH Research PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GH Research PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GH Research PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GH Research PLC equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GHRS by Market Capitalization
Companies near GH Research PLC in the global market cap rankings as of November 4, 2026. Also see GH Research PLC (GHRS) total assets for a full breakdown of the balance sheet.
Key companies related to GH Research PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of GH Research PLC (2021–2026)
Market capitalization of GH Research PLC from 2021 to today. Between 2021 and today, GH Research PLC's market cap moved from $1.60 Billion to $ 1.39 Billion, with a yearly change of 0.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.39 Billion | +59.69% |
| 2025 | $871.76 Million | +81.43% |
| 2024 | $480.50 Million | +20.69% |
| 2023 | $398.13 Million | -40.33% |
| 2022 | $667.20 Million | -58.34% |
| 2021 | $1.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of GH Research PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.39 Billion USD |
| MoneyControl | $1.39 Billion USD |
| MarketWatch | $1.39 Billion USD |
| marketcap.company | $1.39 Billion USD |
| Reuters | $1.39 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more